John G. Clement, PhD - Director and Chief Technical & Development Officer
Dr. Clement possesses over twenty years of experience in pre-clinical and clinical drug development, project management, and product acquisition. Most recently, Dr. Clement served as director of business development at QLT Inc., one of Canada's largest biotechnology companies and the developer of Visudyne, a product used to treat age-related macular degeneration. Dr. Clement has also served as director of extramural research and associate director of biochemical pharmacology and toxicology at Biochem Pharma Inc., which developed the AIDS drug 3TC, as a research scientist and manager with the Department of National Defence and as a research scientist with CIBA-Geigy Canada Ltd. During his tenure with the Department of National Defence, Dr. Clement held various scientific leadership/management positions and was responsible for the development of a new antidote for nerve agent poisoning (HI-6). Dr. Clement received a PhD in pharmacology from the University of Western Ontario and has published over 60 peer reviewed scientific articles.
William Jarosz, JD - Director
William Jarosz is currently a partner at Cartesian Capital Group, LLC,
a global investment management firm. From 1997 until 2005, Mr. Jarosz
served as managing director and general counsel of AIG Capital Partners, a
subsidiary of American International Group, Inc., and as managing director
of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr.
Jarosz oversaw global private equity transactions for the firm's various
private equity f
|SOURCE Beanstalk Capital Ltd.|
Copyright©2007 PR Newswire.
All rights reserved